Get the Stockscreener App
7.33
5.16%
0.36
Pre-market:
7.13
-0.20
-2.73%
Arcturus Therapeutics Holdings Inc stock is traded at $7.33, with a volume of 261.91K.
It is up +5.16% in the last 24 hours and down -1.87% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
See More
Previous Close:
$6.97
Open:
$7.14
24h Volume:
261.91K
Relative Volume:
0.59
Market Cap:
$208.34M
Revenue:
$67.22M
Net Income/Loss:
$-65.78M
P/E Ratio:
-3.0712
EPS:
-2.3867
Net Cash Flow:
$-79.02M
1W Performance:
+2.95%
1M Performance:
-1.87%
6M Performance:
+1.10%
1Y Performance:
-40.79%
1-Day Range:
$7.14
$7.39
1-Week Range:
$6.71
$7.4301
52-Week Range:
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.33 | 208.34M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-26 | Initiated | B. Riley Securities | Buy |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Oct-24-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-23-25 | Downgrade | Citigroup | Buy → Neutral |
| Oct-22-25 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| May-28-25 | Initiated | Scotiabank | Sector Outperform |
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant - Stock Titan
Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options - Stock Titan
Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant - Stock Titan
Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30 - Stock Titan
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant - Stock Titan
Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options - Stock Titan
Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options - Stock Titan
Arcturus Therapeutics highlights mRNA pipeline, CF data and vaccine expansion at Jefferies - MSN
Behavioral Patterns of ARCT and Institutional Flows - Stock Traders Daily
Arcturus Therapeutics Holdings Inc. 2026 Annual Shareholder Meeting Results and Election of Directors - Minichart
Arcturus Shareholders Back Board, Pay, and Auditor - TipRanks
Arcturus Therapeutics (ARCT) holders elect board, approve pay and auditor - Stock Titan
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies - Barchart.com
Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next - Bez Kabli
Arcturus Therapeutics Holds Steady at $7.92 as Market Awaits CatalystsMomentum ETF - newsline.com
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Arcturus Therapeutics Poised for a Massive Upside in 2026 - Kavout
Arcturus Therapeutics (ARCT) Holds Steady at $7.92 – Waiting for a CatalystTriple EMA - newsline.com
Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026 - Traders Union
Arcturus Therapeutics (ARCT) Surges 6.2% as Buyers Defend Key SupportFibonacci Extension - thelegaladvocate.com
Arcturus Therapeutics urges new solutions as 10 percent of cystic fibrosis patients still lack effective treatment - Traders Union
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace
mRNA drug maker Arcturus hits Jefferies 2026 healthcare stage in New York - Stock Titan
Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2026 Earnings: Narrower Net Loss Beats Estimates Amid Pipeline ProgressEarnings Miss Streak - newsline.com
ARCT Q1 2026 Earnings: Arcturus Beats EPS Estimates Amid Pre‑Revenue Phase, Stock Edges HigherQuarterly Earnings Report - newsline.com
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating - Moomoo
How (ARCT) Movements Inform Risk Allocation Models - Stock Traders Daily
Arcturus Therapeutics unveils OTC deficiency research at SIMD 2026 Annual Meeting - Traders Union
Arcturus Therapeutics Holdings Inc (NQ: ARCT - FinancialContent
HC Wainwright & Co. Maintains Arcturus Therapeutics Holdings (ARCT) Neutral Recommendation - MSN
ARCTURUS THERAPEUTICS HOLDINGS INC UPSWING STARTED | ARCT STOCK NEWS (VWpPDIK5Ud) - fathomjournal.org
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating, Maintains Target Price $9 - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Hold Rating - Moomoo
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q1 2026 Earnings Call Transcript - Insider Monkey
MSN Money - MSN
Roth MKM Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arcturus Therapeutics Holdings Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Arcturus Therapeutics (ARCT) Reports Progress in Q1 2026 Earnings Call - GuruFocus
Arcturus Therapeutics Announces First Quarter 2026 Financial Results and Pipeline Progress - BioSpace
ARCT Should I Buy - Intellectia AI
Earnings call transcript: Arcturus Therapeutics Q1 2026: EPS Beat, Revenue Decline - Investing.com
Trading Systems Reacting to (ARCT) Volatility - Stock Traders Daily
ARCT: Advanced rare disease pipeline, reduced expenses, and strong cash position support 2026 milestones - TradingView
ARCT: Achieved key clinical milestones in rare disease mRNA programs with strong financial runway - TradingView
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Biotechnology company Arcturus Therapeutics Holdings Inc. recently announced through a filing with the U.S. Securities and Exchange Commission (SEC) that Mr. Dennis Mulroy has been officially appointed as the company's Chief Financial Officer (CFO), eff - Bitget
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline - TipRanks
Arcturus Therapeutics Q1 Earnings Call Highlights - Yahoo Finance
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2026 Results: Revenue Miss Weighs on Sentiment as Pipeline Advances - ChartMill
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):